{"id":70674,"date":"2026-05-12T09:08:38","date_gmt":"2026-05-12T09:08:38","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70674"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"tirzepatide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/fr\/product\/tirzepatide\/","title":{"rendered":"Tirzepatide"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">R\u00e9ponse rapide \u2014 Qu'est-ce que le Tirzepatide ?<\/h3>\n<p style=\"margin: 0;\"><strong>Tirzepatide<\/strong> is a 39-amino-acid dual GLP-1 and GIP receptor co-agonist peptide and the active studies molecule behind Mounjaro and Zepbound. It produces the largest body-weight and glycaemic effect of any single peptide in current published studies, with the dual-receptor profile delivering a meaningfully greater response than single GLP-1 agonists in head-to-head trials such as SURPASS-2. Plasma half-life is approximately 120 hours (~5 days), enabling once-weekly dosing. Supplied in 5\u00a0mg to 120\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Ce que vous obtenez avec MedsBase :<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/fr\/reviews\/\">avis clients<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Chaque commande est couverte par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\"><strong>Politique de R\u00e9exp\u00e9ditions Garanties<\/strong><\/a> \u2014 si votre colis n'arrive pas dans les 20 jours ouvrables, nous le r\u00e9exp\u00e9dions.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Sp\u00e9cification<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">D\u00e9tail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Num\u00e9ro CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2023788-19-2<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Formule mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>225<\/sub>H<sub>348<\/sub>N<sub>48<\/sub>O<sub>68<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Masse mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">4813.45 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>S\u00e9quence<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Y-Aib-EGTFTSDYSI-Aib-LDKIAQKAFVQWLIAGGPSSGAPPPS (39 aa, squelette bas\u00e9 sur GIP avec Aib<sup>2<\/sup>, Aib<sup>13<\/sup>, et Lys<sup>20<\/sup>-C20 diacide gras acyl\u00e9s via espaceur \u03b3Glu-\u03b3Glu)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forme<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Poudre lyophilis\u00e9e (blanche \u00e0 blanc cass\u00e9)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Puret\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599 % (v\u00e9rifi\u00e9 par HPLC, COA sur demande)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Stockage<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilis\u00e9 : 2\u20138 \u00b0C (r\u00e9frig\u00e9rateur) pour le stock de travail ; \u221220 \u00b0C pour le stockage \u00e0 long terme des flacons non ouverts. Reconstitu\u00e9 : 2\u20138 \u00b0C, \u00e0 utiliser dans ~30 jours. Prot\u00e9ger de la lumi\u00e8re. Ne pas congeler-d\u00e9congeler la solution reconstitu\u00e9e.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilit\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Eau bact\u00e9riostatique (recommand\u00e9e) ou eau st\u00e9rile pour des fen\u00eatres d'utilisation plus courtes<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Qu'est-ce que le Tirzepatide ?<\/h2>\n<p><strong>Tirzepatide<\/strong> is a 39-amino-acid dual incretin receptor co-agonist that activates both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors with comparable potency. Developed by Eli Lilly and disclosed in 2018, it was the first dual-incretin agonist to reach regulatory approval (Mounjaro for type 2 diabetes in 2022, Zepbound for chronic weight management in 2023). Tirzepatide is built on the GIP peptide backbone \u2014 not the GLP-1 backbone used by semaglutide \u2014 with two \u03b1-aminoisobutyric acid (Aib) substitutions at positions 2 and 13 that resist DPP-4 cleavage and a C20 fatty diacid attached at lysine 20 via two \u03b3-glutamic acid spacers. The C20 acyl chain is one carbon longer than semaglutide&#8217;s C18, producing tighter albumin binding and a slightly different pharmacokinetic profile. Tirzepatide&#8217;s well-characterised structure has empirical formula C<sub>225<\/sub>H<sub>348<\/sub>N<sub>48<\/sub>O<sub>68<\/sub> with average molecular weight 4813.45 Da. Plasma half-life is approximately 120 hours (~5 days), enabling once-weekly subcutaneous dosing in published studies. The compound is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. For broader incretin studies, see our <a href=\"https:\/\/medsbase.com\/fr\/semaglutide\/\">Semaglutide<\/a> et <a href=\"https:\/\/medsbase.com\/fr\/retatrutide\/\">Retatrutide<\/a> pages produit. <\/p>\n<h2>M\u00e9canisme d'action \u2014 Co-agonisme double des r\u00e9cepteurs GLP-1\/GIP<\/h2>\n<p>Ce qui diff\u00e9rencie le tirzepatide des peptides incr\u00e9tines simples pr\u00e9c\u00e9dents est son <strong>activation \u00e9quilibr\u00e9e de deux r\u00e9cepteurs distincts<\/strong>, each contributing complementary metabolic effects observed in published studies:<\/p>\n<ul>\n<li><strong>Activation du r\u00e9cepteur GLP-1 \u2014 sati\u00e9t\u00e9, s\u00e9cr\u00e9tion d'insuline par les cellules \u03b2, vidange gastrique<\/strong> \u2014 Le tirzepatide se lie au r\u00e9cepteur GLP-1 avec une affinit\u00e9 comparable au GLP-1 natif, activant l'ad\u00e9nylyl cyclase coupl\u00e9e \u00e0 G\u03b1<sub>s<\/sub>et la signalisation en aval cAMP\/PKA. Cela produit les effets canoniques du GLP-1 : potentialisation glucose-d\u00e9pendante de la s\u00e9cr\u00e9tion d'insuline par les cellules \u03b2 pancr\u00e9atiques, suppression du glucagon par les cellules \u03b1, retard de la vidange gastrique et effets centraux de suppression de l'app\u00e9tit via les neurones POMC du noyau arqu\u00e9. Ce m\u00e9canisme recoupe celui du s\u00e9maglutide.<\/li>\n<li><strong>Activation du r\u00e9cepteur GIP \u2014 lipolyse des adipocytes, d\u00e9pense \u00e9nerg\u00e9tique, soutien des cellules \u03b2<\/strong> \u2014 The GIP component is what makes tirzepatide pharmacologically distinct. GIP receptor activation enhances insulin secretion in a glucose-dependent manner (complementary to GLP-1&#8217;s effect), but also acts on adipocytes to promote lipolysis under fasting conditions while supporting triglyceride storage in the fed state. Studies suggests GIP-receptor signaling also raises resting energy expenditure modestly and acts in CNS regions distinct from GLP-1, including the dorsomedial hypothalamus. The net effect is an additive body-weight signal beyond what GLP-1 alone produces.<\/li>\n<li><strong>\u00c9quilibre des r\u00e9cepteurs et ajustement structurel fin<\/strong> \u2014 In radioligand-binding assays, tirzepatide shows higher affinity for the GIP receptor than for the GLP-1 receptor \u2014 an unusual ratio that distinguishes it from earlier dual-agonist candidates. The asymmetry is intentional: the GIP backbone allows higher GIP-receptor potency while the engineered modifications preserve sufficient GLP-1 activity. Tirzepatide is sometimes described as &#8220;GIP-biased&#8221; in receptor pharmacology, which has implications for the differential signalling observed in study models.<\/li>\n<\/ul>\n<p>The C20 fatty diacid acyl tether at lysine 20 binds reversibly to circulating serum albumin, forming a peptide depot that protects tirzepatide from renal clearance and produces the ~120-hour plasma half-life. The double Aib substitution (positions 2 and 13) prevents DPP-4 cleavage at two distinct sites, providing redundant proteolytic protection. Together these structural features convert what would otherwise be a short-acting incretin into a once-weekly peptide. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Tirzepatide is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Contr\u00f4le glyc\u00e9mique et sensibilit\u00e9 \u00e0 l'insuline<\/strong> \u2014 comparaison directe avec le s\u00e9maglutide et d'autres monoagonistes GLP-1 (Frias et al., NEJM 2021 SURPASS-2) ; mod\u00e8les rongeurs db\/db, ZDF et r\u00e9gime riche en graisses ; effets sur les substituts d'HbA1c, la glyc\u00e9mie \u00e0 jeun et les param\u00e8tres de clamp hyperinsulin\u00e9mique-euglyc\u00e9mique<\/li>\n<li><strong>Body weight and adiposity studies<\/strong> \u2014 the SURMOUNT-1 trial showed ~22% body weight reduction at 15\u00a0mg weekly over 72 weeks, the largest single-peptide effect documented in clinical studies at the time; rodent DIO models, body composition (DEXA \/ MRI), respiratory exchange ratio<\/li>\n<li><strong>MASLD\/MASH (maladie h\u00e9patique associ\u00e9e \u00e0 la dysfonction m\u00e9tabolique)<\/strong> \u2014 contenu en triglyc\u00e9rides h\u00e9patiques, ALT\/AST, stadification de la fibrose ; jeu de donn\u00e9es de l'essai SYNERGY-NASH<\/li>\n<li><strong>Cardiovascular studies<\/strong> \u2014 effets sur la pression art\u00e9rielle, les profils lipidiques, la progression de l'ath\u00e9roscl\u00e9rose chez les ApoE<sup>-\/-<\/sup> Recherche sur l'apn\u00e9e du sommeil<\/li>\n<li><strong>Sleep apnoea studies<\/strong> \u2014 s\u00e9v\u00e9rit\u00e9 de l'apn\u00e9e obstructive du sommeil, index apn\u00e9e-hypopn\u00e9e dans le jeu de donn\u00e9es SURMOUNT-OSA<\/li>\n<li><strong>Protection r\u00e9nale dans les mod\u00e8les de n\u00e9phropathie diab\u00e9tique<\/strong> \u2014 albuminurie, d\u00e9bit de filtration glom\u00e9rulaire, expansion m\u00e9sangiale dans la maladie r\u00e9nale diab\u00e9tique induite par la streptozotocine et chez la souris Akita<\/li>\n<li><strong>Comparative incretin peptide studies<\/strong> \u2014 r\u00e9f\u00e9rence pour les comparaisons agoniste double vs agoniste simple vs agoniste triple. Voir notre <a href=\"https:\/\/medsbase.com\/fr\/retatrutide-vs-tirzepatide\/\">Guide Retatrutide vs Tirzepatide<\/a> ainsi qu'au <a href=\"https:\/\/medsbase.com\/fr\/semaglutide\/\">Semaglutide<\/a> page produit pour les comparateurs apparent\u00e9s.<\/li>\n<\/ul>\n<p>Pour un contexte plus large sur la place du tirzepatide dans le paysage des peptides m\u00e9taboliques, consultez <a href=\"https:\/\/medsbase.com\/fr\/retatrutide\/\">Retatrutide<\/a> (agoniste triple GLP-1\/GIP\/glucagon, le comparateur de nouvelle g\u00e9n\u00e9ration) et <a href=\"https:\/\/medsbase.com\/fr\/ozempic-vs-mounjaro\/\">notre guide Ozempic vs Mounjaro<\/a>. Parcourez l'int\u00e9gralit\u00e9 de notre <a href=\"https:\/\/medsbase.com\/fr\/peptides\/\">catalogue de peptides<\/a> pour les compos\u00e9s associ\u00e9s. <\/p>\n<h2>Forces et concentrations disponibles<\/h2>\n<p>MedsBase stocks Tirzepatide in eleven lyophilized vial strengths covering the full dose-titration range from pilot dosing through multi-month bulk protocols. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Concentration du flacon<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Cas d'utilisation typique<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tailles de conditionnement<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Dosage pilote, titration de bas niveau, cycles courts<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Maintenance strength, mid-titration<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>15\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Puissance cible \u00e9quivalente clinique (dose humaine maximale approuv\u00e9e)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>20\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">High-dose arm, exploratory protocols<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>30\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocoles de plusieurs semaines \u00e0 partir d'un seul flacon, volume de reconstitution r\u00e9duit<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>40\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Extended-cycle studies, lower per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>50\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Multi-month protocols, comparative dose-response studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>60\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">High-dose comparative arm<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>80\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Bulk packs vial, low per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>100\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u00c9tudes multi-cohortes, protocoles de plusieurs mois<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>120\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Maximum Bulk packs vial, lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All eleven strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful for users minimising injection volume or running extended multi-month protocols from a single vial. Because reconstituted solution is stable for ~30 days, the optimal vial size for a given protocol depends on weekly dose \u00d7 weeks-per-vial trade-off. <\/p>\n<h2>Comparaison \u2014 Tirzepatide vs Semaglutide vs Retatrutide<\/h2>\n<p>Tirzepatide sits at the centre of the modern incretin-agonist studies landscape, between the single-receptor <a href=\"https:\/\/medsbase.com\/fr\/semaglutide\/\">Semaglutide<\/a> (GLP-1 uniquement) et le r\u00e9cepteur triple <a href=\"https:\/\/medsbase.com\/fr\/retatrutide\/\">Retatrutide<\/a> (GLP-1 + GIP + glucagon). Each step up the receptor ladder produces a progressively larger body-weight effect in head-to-head studies but also broader systemic signalling. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e8re<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Semaglutide<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tirzepatide<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Retatrutide<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Profil des r\u00e9cepteurs<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 (simple)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP (double)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP + glucagon (triple)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Structure peptidique<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 (31 aa)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GIP (39 aa)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Similaire au GIP (39 aa)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Demi-vie<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~165 heures (~7 jours)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~120 heures (~5 jours)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~6 jours<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Ancre d'acide gras<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Diacide C18 + AEEA-AEEA<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Diacide C20 + \u03b3Glu-\u03b3Glu<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Diacide C20 + \u03b3Glu<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>R\u00e9f\u00e9rence de marque<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ozempic \/ Wegovy \/ Rybelsus<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Mounjaro \/ Zepbound<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">En cours d'\u00e9tude (LY3437943)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Typical weekly dose<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">0,25\u20132,4 mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">2,5\u201315 mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">2\u201312 mg<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Effet sur le poids corporel dans les essais<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~15 % (STEP)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~22 % (SURMOUNT-1)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~24 % (Phase 2)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Strongest signal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Contr\u00f4le glyc\u00e9mique, cardiovasculaire<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Combinaison glyc\u00e9mie + poids corporel, MASH<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Effet sur le poids corporel le plus important<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The head-to-head SURPASS-2 trial (Frias et al., NEJM 2021) showed superior HbA1c and body-weight reduction with tirzepatide 15\u00a0mg vs semaglutide 1\u00a0mg over 40 weeks \u2014 one of the largest direct comparison datasets in incretin studies. For methodological detail on the dual- vs triple-agonist landscape, read <a href=\"https:\/\/medsbase.com\/fr\/retatrutide-vs-tirzepatide\/\">Retatrutide vs Tirzepatide : agoniste triple vs double<\/a> et <a href=\"https:\/\/medsbase.com\/fr\/ozempic-vs-mounjaro\/\">Ozempic vs Mounjaro<\/a>. Users selecting between these peptides typically weigh receptor selectivity (cleaner pharmacology with semaglutide), magnitude of effect (greater with tirzepatide and retatrutide), and the strength of available trial data (extensive for semaglutide and tirzepatide, still maturing for retatrutide). <\/p>\n<h2>Stockage et reconstitution<\/h2>\n<p><strong>Avant la reconstitution :<\/strong> conserver les flacons lyophilis\u00e9s au r\u00e9frig\u00e9rateur entre 2 et 8 \u00b0C dans leur emballage d'origine pour un stock de travail \u00e0 court terme. Pour un stockage \u00e0 long terme non ouvert, congeler \u00e0 \u221220 \u00b0C. Le tirzepatide lyophilis\u00e9 est stable sous r\u00e9frig\u00e9ration jusqu'\u00e0 24 mois et \u00e0 \u221220 \u00b0C jusqu'\u00e0 36 mois. \u00c9viter les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation de la poudre lyophilis\u00e9e. <strong>Proc\u00e9dure de reconstitution :<\/strong> injecter de l'eau bact\u00e9riostatique le long de la paroi lat\u00e9rale du flacon de peptide (pas directement sur le g\u00e2teau lyophilis\u00e9). Pour un flacon de 10 mg, 2,0 mL d'eau bact\u00e9riostatique donnent une concentration de travail de 5 mg\/mL \u2014 10 graduations sur une seringue \u00e0 insuline U-100 \u00e9quivalent \u00e0 500 mcg. Agiter doucement \u2014 ne pas <strong>re\u00e7oit pas<\/strong> secouer \u2014 et laisser 2 \u00e0 5 minutes pour une dissolution compl\u00e8te. Une solution correctement reconstitu\u00e9e doit \u00eatre claire et incolore. <strong>Apr\u00e8s reconstitution :<\/strong> store refrigerated at 2\u20138\u00a0\u00b0C and use within 30 days for optimal stability. Do not freeze the reconstituted solution \u2014 freeze-thaw cycles degrade peptide integrity. Discard any vial showing cloudiness, precipitate, or discolouration. Because tirzepatide is dosed once weekly in protocols, a single reconstituted 10\u00a0mg vial typically supports 2\u20134 weeks of dosing depending on target dose; a 50\u00a0mg vial supports 10\u201320 weeks at clinical-equivalent doses. <\/p>\n<h2 id=\"faqs\">Questions fr\u00e9quemment pos\u00e9es<\/h2>\n<h3>What is Tirzepatide used for in studies?<\/h3>\n<p>Tirzepatide is used in studies investigating glycaemic control, insulin sensitivity, body weight and adiposity, MASLD\/MASH liver disease, cardiovascular endpoints, sleep apnoea, and diabetic nephropathy. It is the most extensively characterised dual GLP-1\/GIP agonist and is the standard comparator arm for newer multi-agonist peptide studies. The pharmaceutical-grade tirzepatide sold here is <strong>re\u00e7oit pas<\/strong> FDA-approved for human therapeutic use and is supplied strictly for clinical studies. <\/p>\n<h3>En quoi le Tirzepatide diff\u00e8re-t-il du Semaglutide ?<\/h3>\n<p>La diff\u00e9rence structurelle r\u00e9side dans le profil des r\u00e9cepteurs et le squelette peptidique. Le Tirzepatide est construit sur le squelette GIP de 39 acides amin\u00e9s et co-active \u00e0 la fois les r\u00e9cepteurs GIP et GLP-1. Le Semaglutide est construit sur le squelette GLP-1 de 31 acides amin\u00e9s et n'active que le r\u00e9cepteur GLP-1. La composante GIP du Tirzepatide ajoute une lipolyse des tissus adipeux et une augmentation modeste de la d\u00e9pense \u00e9nerg\u00e9tique que les peptides uniquement GLP-1 ne produisent pas. Dans les essais comparatifs (SURPASS-2), le Tirzepatide 15 mg a produit une r\u00e9duction sup\u00e9rieure de l'HbA1c et du poids corporel par rapport au Semaglutide 1 mg sur 40 semaines. <\/p>\n<h3>En quoi le Tirzepatide diff\u00e8re-t-il du Retatrutide ?<\/h3>\n<p>Les deux sont bas\u00e9s sur une structure GIP, mais le Retatrutide ajoute une activit\u00e9 sur le r\u00e9cepteur du glucagon en plus du GLP-1 et du GIP \u2014 ce qui en fait un triple agoniste. La composante glucagon suppl\u00e9mentaire contribue davantage \u00e0 la d\u00e9pense \u00e9nerg\u00e9tique et \u00e0 la lipolyse des adipocytes. Les donn\u00e9es publi\u00e9es de Phase 2 du Retatrutide montrent une r\u00e9duction du poids corporel d'environ 24 % \u00e0 12 mg par semaine, d\u00e9passant modestement les 22 % du Tirzepatide dans SURMOUNT-1. Le Tirzepatide dispose d'un ensemble de donn\u00e9es d'essais plus mature ; le Retatrutide est encore en d\u00e9veloppement avanc\u00e9. <\/p>\n<h3>What is the typical Tirzepatide dose?<\/h3>\n<p>Les protocoles publi\u00e9s utilisent g\u00e9n\u00e9ralement un sch\u00e9ma de titration commen\u00e7ant \u00e0 2,5 mg par semaine et augmentant de 2,5 mg toutes les 4 semaines jusqu'\u00e0 une dose d'entretien de 5 \u00e0 15 mg par semaine. Un flacon de 10 mg reconstitu\u00e9 avec 2,0 mL d'eau bact\u00e9riostatique donne 5 mg\/mL \u2014 10 graduations sur une seringue U-100 \u00e9quivalent \u00e0 500 mcg. <\/p>\n<h3>Le Tirzepatide est-il approuv\u00e9 par la FDA ?<\/h3>\n<p>Pharmaceutical tirzepatide is FDA-approved under the brand names Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023), manufactured to GMP standards by Eli Lilly. <\/p>\n<h3>Comment conserver le Tirzepatide ?<\/h3>\n<p>Flacons lyophilis\u00e9s : conserv\u00e9s au r\u00e9frig\u00e9rateur \u00e0 2\u20138 \u00b0C pour les stocks de travail \u00e0 court terme, ou \u00e0 \u221220 \u00b0C pour le stockage \u00e0 long terme des flacons non ouverts. Solution reconstitu\u00e9e : conserv\u00e9e au r\u00e9frig\u00e9rateur \u00e0 2\u20138 \u00b0C, \u00e0 utiliser dans les 30 jours. Ne pas congeler la solution reconstitu\u00e9e \u2014 les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation d\u00e9gradent le peptide. Prot\u00e9ger de la lumi\u00e8re directe en permanence. <\/p>\n<h3>Comment reconstituer le Tirzepatide ?<\/h3>\n<p>Suivez la proc\u00e9dure de reconstitution ci-dessus. Ajoutez de l'eau bact\u00e9riostatique le long de la paroi du flacon (pas directement sur la poudre lyophilis\u00e9e), agitez doucement et laissez reposer 2 \u00e0 5 minutes pour une dissolution compl\u00e8te. Ne <strong>re\u00e7oit pas<\/strong> secouez pas le flacon. Une solution correctement reconstitu\u00e9e est claire et incolore. Pour un flacon de 10 mg + 2,0 mL de diluant, la concentration de travail est de 5 mg\/mL. <\/p>\n<h3>Quelles sont les dosages disponibles chez MedsBase ?<\/h3>\n<p>MedsBase carries Tirzepatide in eleven lyophilized vial strengths: 5\u00a0mg, 10\u00a0mg, 15\u00a0mg, 20\u00a0mg, 30\u00a0mg, 40\u00a0mg, 50\u00a0mg, 60\u00a0mg, 80\u00a0mg, 100\u00a0mg, and 120\u00a0mg. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Quelle est la demi-vie du Tirzepatide ?<\/h3>\n<p>Le Tirzepatide a une demi-vie plasmatique d'environ 120 heures (~5 jours) apr\u00e8s administration sous-cutan\u00e9e. Cette demi-vie est obtenue par liaison r\u00e9versible \u00e0 l'albumine s\u00e9rique via l'ancrage diacide gras C20 au niveau de la lysine 20, ce qui prot\u00e8ge le peptide de la clairance r\u00e9nale. Combin\u00e9 \u00e0 la double substitution Aib (positions 2 et 13) qui bloque la clivage par la DPP-4, cela conf\u00e8re au Tirzepatide un sch\u00e9ma posologique hebdomadaire comparable \u00e0 la demi-vie d'environ 165 heures du s\u00e9maglutide. <\/p>\n<h3>Pourquoi le Tirzepatide entra\u00eene-t-il une perte de poids plus importante que le S\u00e9maglutide ?<\/h3>\n<p>The most-cited mechanism is the GIP-receptor component. GIP-receptor activation contributes additional effects that GLP-1 alone doesn&#8217;t produce: enhanced adipocyte lipolysis under fasting conditions, modest increases in resting energy expenditure, and CNS effects in the dorsomedial hypothalamus distinct from arcuate-nucleus GLP-1 signalling. The combined dual signal produces an additive body-weight reduction beyond GLP-1 alone in head-to-head study models. <\/p>\n<h3>Does Tirzepatide cause side reported effects?<\/h3>\n<p>Le r\u00e9sultat le plus constant est gastro-intestinal \u2014 naus\u00e9es, suppression transitoire de l'app\u00e9tit et vidange gastrique retard\u00e9e sont dose-d\u00e9pendants et ont tendance \u00e0 s'att\u00e9nuer apr\u00e8s 4 \u00e0 8 semaines de dosage continu \u00e0 mesure que la tachyphylaxie des r\u00e9cepteurs se d\u00e9veloppe. Des r\u00e9sultats moins fr\u00e9quents incluent des effets sur la motilit\u00e9 v\u00e9siculaire et (dans les mod\u00e8les rongeurs avec sensibilit\u00e9 des cellules C thyro\u00efdiennes) une hyperplasie des cellules C \u2014 ce dernier \u00e9tant un signal sp\u00e9cifique \u00e0 l'esp\u00e8ce qui ne s'est pas traduit chez l'homme dans le suivi clinique \u00e0 long terme. <\/p>\n<h3>Can Tirzepatide and Semaglutide be compared in studies?<\/h3>\n<p>Oui \u2014 la comparaison directe est l'une des questions les plus \u00e9tudi\u00e9es en pharmacologie des incr\u00e9tines. L'essai clinique SURPASS-2 a directement compar\u00e9 le Tirzepatide 15 mg au S\u00e9maglutide 1 mg chez des patients diab\u00e9tiques de type 2 ; les donn\u00e9es pr\u00e9cliniques et les preuves croissantes en vie r\u00e9elle continuent d'\u00e9tendre la comparaison aux param\u00e8tres de poids corporel, MASH et cardiovasculaires. Le S\u00e9maglutide reste le comparateur GLP-1 standard ; le Tirzepatide est le comparateur standard des agonistes doubles. <\/p>\n<h3>How long does Tirzepatide take to show effects in preclinical studies?<\/h3>\n<p>Acute pharmacodynamic effects on glucose tolerance and gastric emptying are detectable within hours of the first dose. Body-weight effects in DIO rodent models typically become statistically significant after 1\u20132 weeks of weekly dosing and continue to accrue through 8\u201316 weeks. Maximum effect on body composition is typically observed after 16\u201324 weeks of continuous dosing in study models, mirroring the human-trial trajectory. <\/p>\n<h3>Puis-je commander du Tirzepatide pour une livraison internationale ?<\/h3>\n<p>Oui. MedsBase exp\u00e9die le Tirzepatide dans le monde entier depuis notre r\u00e9seau d\u00e9di\u00e9 d'exp\u00e9dition de peptides. Les commandes de peptides uniquement sont \u00e9ligibles \u00e0 notre service d'exp\u00e9dition de peptides autonome. Toutes les commandes sont exp\u00e9di\u00e9es dans un emballage \u00e0 temp\u00e9rature contr\u00f4l\u00e9e avec un suivi complet et sont couvertes par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\">Politique de R\u00e9exp\u00e9ditions Garanties<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Metabolic and Body-Composition Studies<\/h2>\n<ul>\n<li><a href=\"\/fr\/semaglutide\/\"><strong>Semaglutide<\/strong><\/a> \u2014 Single GLP-1 agonist (Ozempic\/Wegovy\/Rybelsus active) \u2014 standard glycaemic and CV-studies comparator<\/li>\n<li><a href=\"\/fr\/retatrutide\/\"><strong>Retatrutide<\/strong><\/a> \u2014 Triple GLP-1\/GIP\/glucagon agonist \u2014 next-generation multi-axis metabolic support<\/li>\n<li><a href=\"\/fr\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 GHRH analog \u2014 visceral adipose tissue studies<\/li>\n<li><a href=\"\/fr\/mots-c\/\"><strong>MOTS-c<\/strong><\/a> \u2014 Mitochondrially-encoded exercise-mimetic peptide \u2014 AMPK and insulin sensitivity<\/li>\n<li><a href=\"\/fr\/cjc-1295-with-dac\/\"><strong>CJC-1295 avec DAC<\/strong><\/a> \u2014 Long-acting GHRH analog for growth-axis studies<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Pour en savoir plus<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Comparez le paysage des incr\u00e9tines \u00e0 action prolong\u00e9e<\/strong><\/p>\n<p style=\"margin: 0;\">Lisez nos guides comparatifs : <a href=\"https:\/\/medsbase.com\/fr\/retatrutide-vs-tirzepatide\/\"><strong>Retatrutide vs Tirzepatide \u2014 triple agoniste vs double agoniste<\/strong><\/a> et <a href=\"https:\/\/medsbase.com\/fr\/ozempic-vs-mounjaro\/\"><strong>Ozempic vs Mounjaro<\/strong><\/a>. Couvre la pharmacologie des r\u00e9cepteurs, l'ing\u00e9nierie des s\u00e9quences, la demi-vie, la relation dose-effet, et les donn\u00e9es d'essais comparatifs qui distinguent le tirzepatide du s\u00e9maglutide (SURPASS-2) et des r\u00e9sultats de Phase 2 du retatrutide en tant que triple agoniste.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Double agoniste des r\u00e9cepteurs GLP-1 + GIP<br \/>\n\u2705 Effet sur le poids corporel le plus important pour un peptide unique<br \/>\n\u2705 Supports glycaemic control<br \/>\n\u2705 Lipolyse des adipocytes et d\u00e9pense \u00e9nerg\u00e9tique<br \/>\n\u2705 Protocoles de dosage hebdomadaire<\/p>\n<p><strong>Tirzepatide<\/strong> contient un compos\u00e9 peptidique synth\u00e9tique.<\/p>","protected":false},"featured_media":70986,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[5441,5418],"class_list":["post-70674","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-peptide","product_tag-tirzepatide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product\/70674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/comments?post=70674"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media\/70986"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media?parent=70674"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_brand?post=70674"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_cat?post=70674"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_tag?post=70674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}